Down 34% in 3 months while the S&P 500 fell 5%.
−3Long-term trend
HROW's Quality Score rose 2 points on Fri, Nov 6, to -1. It closed near its high of the day (2 chart checks started).
Follow HROW's trial news. Pro members can get an alert when Harrow files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Since its 2024 high | Down 55% |
| Latest filing | 8-K, Oct 5 |
ReportReports today, after the close. Every 3 months, a company tells everyone how much it sold and earned. It fell after 3 of its last 4 reports, -10.3% on average. Past reports ›
Tue Nov 10: Q3 2026 Earnings Conference CallDate confirmed.
After its last 4 reports it closed -10.3% on average, higher 1 of 4 times.
No shelf registration or at-the-market program on file in the last three years.
Chief Scientific Officer Amir Shojaei sold 11,250 shares on Aug 14. 4 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
HROW is #63 of 90 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 63 |
Reports Mon Nov 9, after the close (today). Confirmed.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
The figures are not read from the release yet.
“During the quarter, branded revenue, net, grew 33% year over year to $56.1 million, partially offset by ImprimisRx revenue of $14.6 million, which declined from $21.5 million in the prior-year second quarter as a result of discontinuation of Klarity-C,exiting the California market, and the transition of certain compounded units to branded units.”
HROW's results filing gives no sales by line in a table we read.
| Measure | Figure |
|---|---|
| Revenue | $350M to $365M |
“We expect ImprimisRx revenue to improve over the balance of 2026.”
From its results filing (SEC filing · Aug 10)
Sales grew 45% a year over 3 years, fiscal 2022 to 2025.
Its share count grew 7.3% a year over 5 years.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Aug 10, 2026 | -4.2% | -3.1% | -3.0% |
| May 11, 2026 | -11.0% | -23.7% | -18.8% |
| Mar 2, 2026 | -16.7% | -28.0% | -34.4% |
Sales grew in six of the last seven years, to $272M in 2025. It made a profit in two of the eight years.
RSI 36.7, MACD above signal, below both averages. Not scored.
4 insiders bought $469K across 4 filings, and one insider sold $450K across 1 filing, in the last 6 months. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: HROW is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.
HROW scores -1 today, which Breakaway calls Poor. It is #63 of 90 in Pharma by Quality Score, with 2 of 14 chart checks firing. Down 34% in 3 months while the S&P 500 fell 5%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
HROW scores -1 today, which Breakaway calls Poor (below zero). That is #63 of 90 in Pharma by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind HROW's -1.
4 insiders bought $469K across 4 filings, and one insider sold $450K across 1 filing, in the last 6 months. The newest is Amir Shojaei, Chief Scientific Officer, who sold $450K on Aug 14. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until tomorrow morning. No account. No card. Then keep going with a free account.